225 related articles for article (PubMed ID: 21555762)
1. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
[TBL] [Abstract][Full Text] [Related]
2. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
3. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S; Nunes S; Gomes Neto A
An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
[TBL] [Abstract][Full Text] [Related]
4. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
5. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
7. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
10. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
11. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
13. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Ulbricht H; Wörz K
Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
15. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
17. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
Brenner MA; Harkless LB; Mendicino RW; Page JC
J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
[TBL] [Abstract][Full Text] [Related]
18. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
19. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
